What the Long-Term Data Shows

The most relevant clinical data for 18-month semaglutide results comes from the STEP trial program:

• STEP 1 (68 weeks / ~16 months): Participants on semaglutide 2.4 mg lost an average of 14.9% of body weight. For a 230-pound person, that is roughly 34 pounds .
• STEP 5 (104 weeks / 2 years): This extended trial showed sustained weight loss of approximately 15.2% of body weight at 2 years. At the 18-month mark (78 weeks), weight loss had largely plateaued, meaning most patients had reached their maximum benefit .
• STEP 3 (with intensive behavioral therapy): Patients who combined semaglutide with structured lifestyle counseling lost up to 16% of body weight, with results holding at 18 months.

The consistent finding across these trials is that weight loss with semaglutide reaches a plateau between months 12 and 18. After that, the focus shifts from losing weight to maintaining it.

Timeline: From Start to 18 Months

• Months 1 to 4 (titration): Gradual dose escalation from 0.25 mg to 2.4 mg. Weight loss of 4 to 10 pounds. Body adjusting to medication.
• Months 5 to 8 (active loss): Fastest rate of weight loss. Roughly 1 to 2 pounds per week. Cumulative loss of 15 to 25 pounds.
• Months 9 to 12 (continued loss, slowing): Rate gradually declines. Cumulative loss of 25 to 35 pounds. Metabolic adaptation begins.
• Months 13 to 15 (approaching plateau): Weight loss slows considerably. Cumulative loss of 30 to 38 pounds. Focus shifts toward habit consolidation.
• Months 16 to 18 (plateau/maintenance): Most patients have reached or are very close to their maximum weight loss. Cumulative loss of 30 to 40+ pounds. The body has established a new metabolic setpoint.

Health Improvements Beyond Weight at 18 Months

By 18 months, many patients experience meaningful improvements across multiple health markers:

• Blood sugar: A1C reductions of 1.0% to 1.8% in patients with prediabetes or type 2 diabetes .
• Cardiovascular health: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a median follow-up of 40 months .
• Blood pressure: Systolic reductions of 3 to 6 mmHg are commonly observed.
• Liver health: Improvements in liver fat content and ALT levels, particularly relevant for patients with NAFLD .
• Sleep quality: Reduced sleep apnea severity and improved sleep patterns are frequently reported by patients who lose 10% or more of body weight.
• Joint pain: Lower mechanical stress on knees, hips, and ankles often results in notable pain reduction.

The Plateau Phase: What Is Happening

It is completely normal for weight loss to plateau around months 12 to 18. This does not mean semaglutide has stopped working. Here is what is actually happening:

• Metabolic adaptation: As you weigh less, your body burns fewer calories at rest. The caloric deficit that initially drove weight loss narrows.
• Hormonal rebalancing: Leptin and ghrelin levels adjust to your new weight, influencing hunger and satiety signals.
• New equilibrium: Your body has found a balance between the appetite-suppressing effects of semaglutide and your caloric needs at a lower weight.

The medication continues to prevent weight regain, which is itself a major benefit. Without continued treatment, the body's natural drive to return to its previous weight is strong .

What to Do at the 18-Month Mark

• Review your labs: Get comprehensive bloodwork including A1C, lipid panel, liver enzymes, and kidney function. Compare to your baseline values.
• Reassess your dose: If you are maintaining well, your provider might explore whether a slightly lower dose could sustain results with fewer side effects.
• Evaluate body composition: A DEXA scan can reveal how much lean mass you have preserved. If muscle loss is significant, adjust your exercise and protein intake.
• Strengthen lifestyle habits: By 18 months, the habits you have built should be able to support a good portion of your weight management independently.
• Plan for the long term: Discuss with your provider whether continued treatment, dose reduction, or a structured taper is appropriate for your situation.

Frequently Asked Questions

Should I stay on semaglutide after 18 months?

For most patients, continuing treatment is advisable. The STEP 1 extension trial showed that patients who stopped semaglutide regained about two-thirds of their lost weight within a year . Long-term treatment helps maintain results.

Can I switch to a different medication at 18 months?

Some patients who plateau on semaglutide explore switching to tirzepatide (Mounjaro/Zepbound), which has shown greater weight loss in head-to-head comparisons. Your provider can guide this transition based on your response and goals.

Is it safe to take semaglutide for 18 months or longer?

Long-term safety data from trials extending to 2+ years and real-world use supports ongoing treatment. The SELECT trial followed patients for up to 5 years and found a favorable safety profile . Regular monitoring by your physician remains important .

Why has my weight loss completely stopped?

A true plateau lasting more than 6 to 8 weeks may warrant a conversation with your provider. Possible strategies include increasing physical activity, adjusting macronutrient ratios, addressing sleep or stress issues, or evaluating whether a dose adjustment or medication switch could help.

Will I need a higher dose to keep losing weight?

If you are already on the maximum dose (2.4 mg for Wegovy, or 2.0 mg for Ozempic), there is no approved higher dose. At that point, additional weight loss depends on lifestyle optimization or considering a different medication class.

Continue Your Progress with Expert Guidance

Reaching 18 months on semaglutide is a significant accomplishment. Whether you are maintaining your results, looking to break through a plateau, or considering your next steps, working with a knowledgeable provider makes all the difference. FormBlends offers ongoing clinical support for patients at every stage of their GLP-1 journey.

Schedule a follow-up consultation to plan your next phase of treatment.